Investment
Features
FeesSafety
Academy
More
Pluang+

Halozyme licenses Hypercon tech to Vertex for up to 3 drug targets with $15M upfront payment

Company Fundamentals
07 Apr 2026
PRNewsWire
View Source
Bullish
pluang ai news

Halozyme Therapeutics' subsidiary, Halozyme Hypercon, has entered a global exclusive license agreement with Vertex Pharmaceuticals to use its Hypercon™ technology for up to three drug targets. Hypercon™ allows hyperconcentration of drugs, reducing injection volume and enabling easier at-home administration. Vertex paid $15 million upfront and may provide milestone payments, with Halozyme earning royalties on future sales. This collaboration highlights the potential of Hypercon™ to improve patient access to biologics and advance treatments for serious diseases.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App